Biogen (BIIB) EBT (2009 - 2026)

Biogen's EBT history runs 18 years deep, the most recent figure standing at $377.7 million for Q1 2026.

• In Q1 2026, EBT rose 21.37% year-over-year to $377.7 million; the TTM figure through Mar 2026 stood at $1.6 billion (down 7.38% YoY), while the FY2025 annual figure was $1.6 billion, down 18.34% from the prior year.
• EBT was $377.7 million for Q1 2026 at Biogen, up from -$56.0 million in the prior quarter.
• In the past five years, EBT ranged from a high of $1.4 billion in Q3 2022 to a low of -$141.2 million in Q3 2023.
• Historically, EBT has averaged $513.5 million across 5 years, with a median of $451.0 million in 2024.
• The sharpest annual moves came in 2024 and 2025: EBT jumped 419.41% in 2024, then sank 119.21% in 2025.
• A 5-year view of EBT shows it stood at $603.8 million in 2022, then plunged by 51.71% to $291.6 million in 2023, then retreated by 0.03% to $291.5 million in 2024, then plunged by 119.21% to -$56.0 million in 2025, then soared by 774.46% to $377.7 million in 2026.
• The last three EBT figures came in at $377.7 million (Q1 2026), -$56.0 million (Q4 2025), and $557.3 million (Q3 2025), per Business Quant data.